Measured by its binding ability in a functional ELISA. Immobilized Anti-CD27 Ligand Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) with a linear range of 0.039-0.156 μg/mL (QC tested).
The purity of FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) was more than 85% and the molecular weight of this protein is around 65-75 kDa verified by SEC-MALS.
Measured by its binding ability in a functional ELISA. Immobilized Anti-CD27 Ligand Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD27 Ligand, His,Flag Tag (Cat. No. CDD-HF2D4) with a linear range of 0.039-0.156 μg/mL (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Cusatuzumab | ARGX-110; JNJ-4550 | Phase 2 Clinical | Argen-X | Hematologic Neoplasms; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous | Details |
CTX-130 | CTX-130 | Phase 1 Clinical | Crispr Therapeutics | Hematologic Neoplasms; Carcinoma, Renal Cell; Lymphoma, T-Cell | Details |
This web search service is supported by Google Inc.